Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67


Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.

Dandona P, Mathieu C, Phillip M, Hansen L, Griffen SC, Tschöpe D, Thorén F, Xu J, Langkilde AM; DEPICT-1 Investigators.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):864-876. doi: 10.1016/S2213-8587(17)30308-X. Epub 2017 Sep 14. Erratum in: Lancet Diabetes Endocrinol. 2017 Dec;5(12 ):e8.


Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group.

N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.


Expression of the eRF1 translation termination factor is controlled by an autoregulatory circuit involving readthrough and nonsense-mediated decay in plants.

Nyikó T, Auber A, Szabadkai L, Benkovics A, Auth M, Mérai Z, Kerényi Z, Dinnyés A, Nagy F, Silhavy D.

Nucleic Acids Res. 2017 Apr 20;45(7):4174-4188. doi: 10.1093/nar/gkw1303.


Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.

Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators.

N Engl J Med. 2017 Jan 5;376(1):32-40. doi: 10.1056/NEJMoa1611688. Epub 2016 Nov 13.


Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial.

Davies MJ, Russell-Jones D, Selam JL, Bailey TS, Kerényi Z, Luo J, Bue-Valleskey J, Iványi T, Hartman ML, Jacobson JG, Jacober SJ; IMAGINE 2 Study Investigators.

Diabetes Obes Metab. 2016 Nov;18(11):1055-1064. doi: 10.1111/dom.12712. Epub 2016 Aug 12.


Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.

Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group.

JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.


Heterogeneous effect of gestational weight gain on birth weight: quantile regression analysis from a population-based screening.

Hulmán A, Witte DR, Kerényi Z, Madarász E, Tänczer T, Bosnyák Z, Szabó E, Ferencz V, Péterfalvi A, Tabák AG, Nyári TA.

Ann Epidemiol. 2015 Feb;25(2):133-7, 137.e1. doi: 10.1016/j.annepidem.2014.11.001. Epub 2014 Nov 10.


Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.

Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB; NN9068-3697 (DUAL-I) trial investigators.

Lancet Diabetes Endocrinol. 2014 Nov;2(11):885-93. doi: 10.1016/S2213-8587(14)70174-3. Epub 2014 Sep 1.


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.


Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.

Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group.

Diabetes Obes Metab. 2014 Feb;16(2):124-36. doi: 10.1111/dom.12187. Epub 2013 Aug 29.


The late steps of plant nonsense-mediated mRNA decay.

Mérai Z, Benkovics AH, Nyikó T, Debreczeny M, Hiripi L, Kerényi Z, Kondorosi É, Silhavy D.

Plant J. 2013 Jan;73(1):50-62. doi: 10.1111/tpj.12015. Epub 2012 Oct 19.


Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group.

Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003.


Prognostic impact of electrocardiographic signs in patients with Type 2 diabetes and cardiovascular disease: results from the PROactive study.

Pfister R, Cairns R, Erdmann E, Schneider CA; PROactive investigators.

Diabet Med. 2011 Oct;28(10):1206-12. doi: 10.1111/j.1464-5491.2011.03281.x.


Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled DIabetic REtinopathy Candesartan Trials.

Porta M, Hainer JW, Jansson SO, Malm A, Bilous R, Chaturvedi N, Fuller JH, Klein R, Orchard T, Parving HH, Sjølie AK; DIRECT Study Group.

Diabetologia. 2011 Jun;54(6):1298-303. doi: 10.1007/s00125-010-2040-1. Epub 2011 Jan 12.


Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial.

Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I; D1680C00001 Investigators.

Int J Clin Pract. 2010 Nov;64(12):1619-31. doi: 10.1111/j.1742-1241.2010.02510.x. Epub 2010 Sep 16.


Maternal glycemia and risk of large-for-gestational-age babies in a population-based screening.

Kerényi Z, Tamás G, Kivimäki M, Péterfalvi A, Madarász E, Bosnyák Z, Tabák AG.

Diabetes Care. 2009 Dec;32(12):2200-5. doi: 10.2337/dc09-1088. Epub 2009 Sep 3.


Abnormal glucose tolerance is associated with diminished postload change in leptin levels in women.

Madarász E, Tabák AG, Speer G, Lakatos P, Kerényi Z, Tamás G.

Diabetes Metab Res Rev. 2009 Oct;25(7):632-8. doi: 10.1002/dmrr.1001.


Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team.

Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6.


The effect of paternal and maternal history of diabetes mellitus on the development of gestational diabetes mellitus.

Tabák AG, Tamás G, Péterfalvi A, Bosnyák Z, Madarász E, Rákóczi I, Kerényi Z.

J Endocrinol Invest. 2009 Jul;32(7):606-10. doi: 10.1007/BF03346517. Epub 2009 May 15.


Carbohydrate metabolism and cardiovascular risk factors 4 years after a pregnancy complicated by gestational diabetes.

Madarász E, Tamás G, Tabák AG, Kerényi Z.

Diabetes Res Clin Pract. 2009 Aug;85(2):197-202. doi: 10.1016/j.diabres.2009.05.001. Epub 2009 May 29.


Supplemental Content

Loading ...
Support Center